mir-218-2 promotes glioblastomas growth, invasion and drug resistance by targeting CDC27

Zhuoying Feng; Luping Zhang; Junchen Zhou; Shuai Zhou; Li li; Xuyan Guo; Guoying Feng; Ze Ma; Wenhua Huang; Fei Huang

doi:10.18632/oncotarget.13850

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

mir-218-2 promotes glioblastomas growth, invasion and drug resistance by targeting CDC27

Zhuoying Feng, Luping Zhang, Junchen Zhou, Shuai Zhou, Li li, Xuyan Guo, Guoying Feng, Ze Ma, Wenhua Huang and Fei Huang _

PDF | HTML | How to cite

Oncotarget. 2017; 8:6304-6318. https://doi.org/10.18632/oncotarget.13850

Metrics: PDF 2066 views | HTML 2943 views | ?

Abstract

Zhuoying Feng1,*, Luping Zhang1,*, Junchen Zhou1, Shuai Zhou1, Li li1, Xuyan Guo1, Guoying Feng1, Ze Ma1, Wenhua Huang2, Fei Huang1

1Institute of Human Anatomy and Histology and Embryology, Otology & Neuroscience Center, Binzhou Medical University, Laishan District, Shandong Province, 264003,China

2Institute of Clinical Anatomy, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China

*These authors contributed to this work equally and should be considered as co-first authors

Correspondence to:

Fei Huang, email: [email protected]

Wenhua Huang, email: [email protected]

Keywords: gliomas, mir-218-2, CDC27, proliferation, invasion

Received: December 28, 2015 Accepted: November 02, 2016 Published: December 10, 2016

ABSTRACT

Glioma has become a significant global health problem with substantial morbidity and mortality, underscoring the importance of elucidating its underlying molecular mechanisms. Recent studies have identified mir-218 as an anti-oncogene; however, the specific functions of mir-218-1 and mir-218-2 remain unknown, especially the latter. The objective of this study was to further investigate the role of mir-218-2 in glioma. Our results indicated that mir-218-2 is highly overexpressed in glioma. Furthermore, we showed that mir-218-2 is positively correlated with the growth, invasion, migration, and drug susceptibility (to β-lapachone) of glioma cells. In vitro, the overexpression of mir-218-2 promoted glioma cell proliferation, invasion, and migration. In addition, the overexpression of mir-218-2 in vivo was found to increase glioma tumor growth. Accordingly, the inhibition of mir-218-2 resulted in the opposite effects. Cell division cycle 27 (CDC27), the downstream target of mir-218-2, is involved in the regulation of glioma cells. Our results indicate that the overexpression of CDC27 counteracted the function of mir-218-2 in glioma cells. These novel findings provide new insight in the application of mir-218-2 as a potential glioma treatment.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13850

Publication Alerts

Post-Publication Promotion

Research Papers:

mir-218-2 promotes glioblastomas growth, invasion and drug resistance by targeting CDC27

Abstract